Skip to content

Free cash flow at other companies

McKesson logo
McKessonMCK
$3.31B-56.3%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
-$21.16M-27.6%
Summit Therapeutics logo
Summit TherapeuticsSMMT
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Calculated from The Oncology Institute, Inc.’s reported figures.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s free cash flow?
The Oncology Institute, Inc. (TOI) reported free cash flow of -$3.26M in Q1 2026.
How has The Oncology Institute, Inc.'s free cash flow changed year-over-year?
The Oncology Institute, Inc.'s free cash flow increased by 38.7% year-over-year, from -$5.32M to -$3.26M.
What is the long-term trend for The Oncology Institute, Inc.'s free cash flow?
Over 3 years (2021 to 2025), The Oncology Institute, Inc.'s free cash flow has grown at a -5.5% compound annual growth rate (CAGR), from -$35.53M to -$29.96M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.